SPP1 and neoplasm: In view of this, OPN is receiving increasing interest as a therapeutic target, and a number of approaches are currently in preclinical development, including several antibodies that interfere with the binding of OPN to its receptors, which have shown promise in animal tumour models [7,32,33,34] and other pathological conditions [35,36].